DUBLIN , July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close...
The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -1.01%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.77%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.49%. September...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.87%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.76%. September E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -1.06%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.23%. September E-mini S&P futures...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop ...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful...
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?